2022-Ra-722-Esgo Phase 2 Study Assessing the Efficacy of Adding Al3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to Chemotherapies in Subjects with Platinum Resistant Ovarian Carcinoma

AuthID
 P-00Y-VYN
10
Author(s)
Carlson, M
·
Lea, J
·
Li, Z
·
Gan, M
·
Chen, J
·
Garcia, A
·
Schlumbrecht, M
·
Pearson, M
·
Huang, M
Document Type
Proceedings Paper
Year published
2022
Published
in Ovarian cancer
Indexing
Crossref®
Google Scholar®
Publication Identifiers
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service